CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

V Brusasco¹, R Hodder², M Miravitlles³, L Korducki⁴, L Towse⁴, S Kesten⁴

¹ Facoltà di Medicina e Chirurgia, Università di Genova, Genova, Italy
² Ottawa Civic Hospital, Ottawa, Ontario, Canada
³ Hospital Universitari Valle Hebron, Servei de Neumologia, Barcelona, Spain
⁴ Boehringer Ingelheim Pharmaceuticals, Germany

Correspondence to:
Correspondence to:
Dr V Brusasco, Dipartimento di Medicina Interna, Università di Genova, Viale Benedetto XV 6, 16132 Genova, Italy;
brusasco{at}dism.unige.it

Background: A study was undertaken to record exacerbations and health resource use in patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching placebos.

Methods: Patients with COPD were enrolled in two 6-month randomised, placebo controlled, double blind, double dummy studies of tiotropium 18 µg once daily via HandiHaler or salmeterol 50 µg twice daily via a metered dose inhaler. The two trials were combined for analysis of heath outcomes consisting of exacerbations, health resource use, dyspnoea (assessed by the transitional dyspnoea index, TDI), health related quality of life (assessed by St George’s Respiratory Questionnaire, SGRQ), and spirometry.

Results: 1207 patients participated in the study (tiotropium 402, salmeterol 405, placebo 400). Compared with placebo, tiotropium but not salmeterol was associated with a significant delay in the time to onset of the first exacerbation. Fewer COPD exacerbations/patient year occurred in the tiotropium group (1.07) than in the placebo group (1.49, p<0.05); the salmeterol group (1.23 events/year) did not differ from placebo. The tiotropium group had 0.10 hospital admissions per patient year for COPD exacerbations compared with 0.17 for salmeterol and 0.15 for placebo (not statistically different). For all causes (respiratory and non-respiratory) tiotropium, but not salmeterol, was associated with fewer hospital admissions while both groups had fewer days in hospital than the placebo group. The number of days during which patients were unable to perform their usual daily activities was lowest in the tiotropium group (tiotropium 8.3 (0.8), salmeterol 11.1 (0.8), placebo 10.9 (0.8), p<0.05). SGRQ total score improved by 4.2 (0.7), 2.8 (0.7) and 1.5 (0.7) units during the 6 month trial for the tiotropium, salmeterol and placebo groups, respectively (p<0.01 tiotropium v placebo). Compared with placebo, TDI focal score improved in both the tiotropium group (1.1 (0.3) units, p<0.001) and the salmeterol group (0.7 (0.3) units, p<0.05). Evaluation of morning pre-dose FEV₁, peak FEV₁ and mean FEV₁ (0–3 hours) showed that tiotropium was superior to salmeterol while both active drugs were more effective than placebo.

Conclusions: Exacerbations of COPD and health resource usage were positively affected by daily treatment with tiotropium. With the exception of the number of hospital days associated with all causes, salmeterol twice daily resulted in no significant changes compared with placebo. Tiotropium also improved health related quality of life, dyspnoea, and lung function in patients with COPD.

Keywords: chronic obstructive pulmonary disease; tiotropium; salmeterol; quality of life

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

V Brusasco, R Hodder, M Miravitlles, L Korducki, L Towse, and S Kesten
Thorax 2006 61: 91. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• O'Donnell, D. E. (2006). Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance. ERR 15: 37-41 [Abstract] [Full Text]  
• Rodriguez-Roisin, R. (2006). Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations. ERR 15: 47-51 [Abstract] [Full Text]  
• Decramer, M. (2006). Tiotropium as essential maintenance therapy in COPD. ERR 15: 51-57 [Abstract] [Full Text]  
• Kesten, S., Jara, M., Wentworth, C., Lanes, S. (2006). Pooled Clinical Trial Analysis of Tiotropium Safety. Chest 130: 1695-1703 [Abstract] [Full Text]  
• Barr, R G, Bourbeau, J, Camargo, C A, Ram, F S F (2006). Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61: 854-862 [Abstract] [Full Text]  
• Dusser, D., Bravo, M-L., Iacono, P., on behalf the MISTRAL study group, (2006). The effect of tiotropium on exacerbations and airflow in patients with COPD.. Eur Respir J 27: 547-555 [Abstract] [Full Text]  
• Soler, M. (2005). Modulation of airway inflammation to prevent exacerbations of COPD. ERR 14: 78-82 [Abstract] [Full Text]  
• Chung, K. F. (2005). The Role of Airway Smooth Muscle in the Pathogenesis of Airway Wall Remodeling in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2: 347-354 [Abstract] [Full Text]  
• Soler-Cataluna, J J, Martinez-Garcia, M A, Roman Sanchez, P, Salcedo, E, Navarro, M, Ochando, R (2005). Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925-931 [Abstract] [Full Text]  
• Vincken, W. (2005). Bronchodilator treatment of stable COPD: long-acting anticholinergics. ERR 14: 23-31 [Abstract] [Full Text]  
• Somand, H., Remington, T. L (2005). Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease. The Annals of Pharmacotherapy 39: 1467-1475 [Abstract] [Full Text]  
• van Noord, J. A., Aumann, J-L., Janssens, E., Smeets, J. J., Verhaert, J., Disse, B., Mueller, A., Cornelissen, P. J. G. (2005). Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26: 214-222 [Abstract] [Full Text]  
• Barnes, P. J., Stockley, R. A. (2005). COPD: current therapeutic interventions and future approaches. Eur Respir J 25: 1084-1106 [Abstract] [Full Text]  
• Alvarez-Mon, M., Miravitlles, M., Morera, J., Callol, L., Alvarez-Sala, J. L. (2005). Treatment With the Immunomodulator AM3 Improves the Health-Related Quality of Life of Patients With COPD. Chest 127: 1212-1218 [Abstract] [Full Text]  
• Cooper, C B, Tashkin, D P (2005). Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 330: 640-644 [Full Text]  
• Casaburi, R., Kukafka, D., Cooper, C. B., Witek, T. J. Jr, Kesten, S. (2005). Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD. Chest 127: 809-817 [Abstract] [Full Text]  
• (2005). Editorial Notice. Thorax 60: 105-105 [Full Text]  
• Gross, N. J. (2004). Tiotropium Bromide. Chest 126: 1946-1953 [Abstract] [Full Text]  
• Mahler, D. A., Huang, S., Tabrizi, M., Bell, G. M. (2004). Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study. Chest 126: 926-934 [Abstract] [Full Text]  
• Calverley, P. M. A. (2004). Reducing the Frequency and Severity of Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 1: 121-124 [Abstract] [Full Text]  
• Barr, R. G. (2004). Management of Chronic Obstructive Pulmonary Disease. JAMA 291: 1066-1067 [Full Text]  
• Cazzola, M., Matera, M. G. (2004). Long-Acting Bronchodilators Are the First-Choice Option for the Treatment of Stable COPD. Chest 125: 9-11 [Full Text]  
• Tashkin, D. P., Cooper, C. B. (2004). The Role of Long-Acting Bronchodilators in the Management of Stable COPD. Chest 125: 249-259 [Abstract] [Full Text]  
• Sin, D. D., McAlister, F. A., Man, S. F. P., Anthonisen, N. R. (2003). Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review. JAMA 290: 2301-2312 [Abstract] [Full Text]  
• (2003). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 8: 163-163 [Full Text]  

eLetters:

Read all eLetters

Reflecting the balance of evidence for salmeterol in COPD

Michael B Devoy

Thorax Online, 23 Jun 2003 [Full text]

Authors' reply

Vito Brusasco, et al.

Thorax Online, 10 Jul 2003 [Full text]